Recent Updates
Recently added Catalysts
ELDN Positive Sentiment Score: 70/100

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Wednesday, November 29, 2023 2 min read
Key Takeaway: Eledon Pharmaceuticals announced that its CEO, Dr. David-Alexandre C. Gros, will present at the Noble Capital Markets' Emerging Growth Equity Conference on December 4, 2023. Dr. Gros is also set to take part in a panel discussion on organ transplantation during the conference, which will be held in Boca Raton, Florida. This opportunity allows Eledon to outline its clinical stage developments and engage with stakeholders in the biotechnology sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eledon Pharmaceuticals is presenting at a significant industry conference.
  • The company's CEO will participate in a discussion about organ transplantation.
  • The event provides a platform for Eledon to showcase its innovative therapies.

Full Press Release Details

IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming NobleCon19 - Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on Monday, December 4, 2023, at 12:00 p.m. EST. Dr. Gros will also participate in a panel discussion titled: The Organ Transplant Revolution, that will take place on Monday, December 4, 2023, at 5:00 p.m. EST. The NobleCon19 conference will take place December 3-5, 2023, in Boca Raton, Florida.
A video webcast of the company overview presentation will be available the following day on the Company's website at https://ir.eledon.com/news-and-events/events, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek: www.channelchek.com, the investor portal created by Noble. The webcast will be archived on Eledon’s website, the NobleCon website, and on Channelchek.com for 90 days following the event.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
stephen@gilmartinir.com
Berry & Company Public Relations
Source: Eledon Pharmaceuticals

Tags

Frequently Asked Questions

When will Eledon present at NobleCon19?

Eledon will present on December 4, 2023, at 12:00 p.m. EST.

What is tegoprubart developed for?

Tegoprubart is being developed for immune modulation in severe conditions.

Where can I watch the company overview presentation?

The presentation will be available on Eledon’s website the day after.

What role does CD40L signaling play in Eledon's research?

CD40L signaling is vital for activating immune cells, making it a research target.

How long will the webcast be available after the event?

The webcast will be archived for 90 days on several platforms.

Tags: ELDN Viatris Investor Conferences Healthcare Eledon Pharmaceuticals Noble Capital Markets tegoprubart organ transplantation biotechnology
Last updated: Nov 29, 2023